Your browser is no longer supported. Please, upgrade your browser.
NEW! We've added Bitcoin charts to our Forex section. ×
Settings
BMY [NYSE]
Bristol-Myers Squibb Company
IndexS&P 500 P/E50.59 EPS (ttm)1.35 Insider Own0.10% Shs Outstand1.67B Perf Week0.98%
Market Cap113.85B Forward P/E29.62 EPS next Y2.31 Insider Trans-19.67% Shs Float1.67B Perf Month3.48%
Income2.25B PEG3.04 EPS next Q0.35 Inst Own73.10% Short Float1.26% Perf Quarter12.08%
Sales16.11B P/S7.07 EPS this Y-22.10% Inst Trans0.49% Short Ratio3.39 Perf Half Y17.53%
Book/sh9.35 P/B7.30 EPS next Y31.32% ROA6.70% Target Price70.94 Perf Year43.71%
Cash/sh4.56 P/C14.97 EPS next 5Y16.66% ROE14.80% 52W Range45.09 - 69.86 Perf YTD16.37%
Dividend1.48 P/FCF577.94 EPS past 5Y-5.90% ROI6.40% 52W High-2.23% Beta0.16
Dividend %2.17% Quick Ratio1.80 Sales past 5Y-3.30% Gross Margin77.20% 52W Low51.47% ATR1.08
Employees25000 Current Ratio1.90 Sales Q/Q6.00% Oper. Margin25.30% RSI (14)62.46 Volatility1.11% 1.50%
OptionableYes Debt/Eq0.48 EPS Q/Q26.80% Profit Margin14.00% Rel Volume0.71 Prev Close68.89
ShortableYes LT Debt/Eq0.46 EarningsMay 19 Payout117.80% Avg Volume6.23M Price68.30
Recom2.30 SMA202.90% SMA503.97% SMA20017.22% Volume4,419,017 Change-0.86%
May-14-15Initiated Berenberg Hold $70
Apr-21-15Upgrade Morgan Stanley Equal-Weight → Overweight $60 → $80
Feb-27-15Reiterated Argus Buy $70 → $78
Jan-12-15Reiterated Argus Buy $62 → $70
Oct-27-14Reiterated MKM Partners Sell $34 → $36
Jul-25-14Reiterated MKM Partners Sell $29 → $34
Jan-15-14Reiterated Argus Buy $58 → $62
Jan-10-14Upgrade Barclays Equal Weight → Overweight $52 → $65
Dec-20-13Reiterated UBS Neutral $48 → $54
Jul-29-13Reiterated Argus Buy $54
Jul-17-13Reiterated Barclays Equal Weight $42 → $45
Jun-04-13Reiterated Argus Buy $46 → $54
Apr-26-13Reiterated MKM Partners Sell $26 → $29
Apr-15-13Reiterated Barclays Equal Weight $33 → $42
Jan-25-13Reiterated UBS Neutral $34 → $36
Jan-09-12Reiterated Barclays Capital Overweight $34 → $36
Oct-19-11Initiated MKM Partners Sell $26
Jun-27-11Reiterated UBS Neutral $28 → $30
Mar-31-11Downgrade Jefferies Buy → Hold $28.50
Mar-28-11Reiterated Barclays Capital Overweight $28 → $30
May-22-15 07:31AM  Bristol-Myers Squibb Receives Positive CHMP Opinion in the European Union for Nivolumab (Opdivo, Nivolumab BMS) for the Treatment of Advanced Squamous Non-Small Cell Lung Cancer in Previously-Treated Patients Business Wire
May-21-15 03:15PM  Bristol-Myers' HCV Combination Designation Amended by FDA - Analyst Blog
12:09PM  Bristol-Myers Faces a Compulsory License for an AIDS Drug in Peru at The Wall Street Journal
May-20-15 02:55PM  Jacobs to Boost Organic Growth on Bristol-Myers Contract - Analyst Blog
09:00AM  Bristol-Myers Squibb Receives Amended U.S. FDA Breakthrough Therapy Designation for Investigational Daclatasvir-based Hepatitis C Regimen Business Wire
May-19-15 03:16PM  Medtronic PLC (MDT), Actavis plc (ACT): Zweig-DiMenna Partners Top Picks from Healthcare Sector at Insider Monkey
08:53AM  5 Big Pharma Stocks to Trade for Breakout Gains at TheStreet
08:00AM  Eric Stonestreet, of Televisions Hit Comedy, Modern Family Joins Forces with Bristol-Myers Squibb to Launch Ready. Raise. Rise. to Honor Those Affected by Cancer and Increase Awareness of Innovative Immuno-Oncology Research Business Wire
May-15-15 07:33PM  Lightning Round: This bargain stock goes to $100 at CNBC
06:00PM  Cramer: This roaring stock is still undervalued
04:21PM  Healthcare Winners and Losers: May 15, 2015
May-14-15 09:31AM  Bristol-Myers-AbbVie Drug Improves Remission in Blood Cancer at Bloomberg
06:19AM  ASCO's immunotherapies update
05:57AM  Coverage initiated on Bristol-Myers by Berenberg
May-13-15 02:36PM  Biotech to watch ahead of ASCO
08:02AM  Bristol-Myers Squibb to Present Data at 2015 American Society of Clinical Oncology (ASCO) Annual Meeting that Demonstrate the Promise of its Broad Immuno-Oncology Portfolio Across Solid Tumors and Blood Cancers Including Multiple Myeloma Business Wire
May-12-15 06:15PM  Bristol-Myers Squibb Announces the Pricing Terms of its Cash Tender Offer For Up to $500 Million Aggregate Principal Amount of its Outstanding Debt Securities Business Wire
09:50AM  Short Sellers Keep Strong Bets Against Big Pharma at 24/7 Wall St.
08:00AM  Bristol-Myers Squibb Announces the Early Results of its Cash Tender Offer For Up to $400 Million Aggregate Principal Amount of its Outstanding Debt Securities; Increases the Maximum Amount of the Tender Offer Business Wire
May-11-15 09:16AM  A.M. Funds Roundup: Warning! Hedge Funds Pose Cyber Risk; Caution over China Proves Costly; at Barrons.com
May-09-15 12:01AM  Big Fan of Apple and Bristol-Myers at Barrons.com
May-08-15 07:04PM  Bristol-Myers Say-On-Pay Vote Squeaks By at The Wall Street Journal
06:00PM  Making Money With Charles Payne: 05/8/15 at Fox Business
04:38PM  BRISTOL MYERS SQUIBB CO Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
02:17PM  2 reasons we're not in biotech bubble: Pro
09:20AM  4 Pharmaceutical Companies Leading the Breast Cancer Fight at 24/7 Wall St.
May-07-15 05:26PM  Biotech stocks to watch: BMY, CLVS & more
May-06-15 06:00PM  Cramer: The play on Whole Foods
11:20AM  Long-Term, 7-Year Study of Nulojix® (belatacept) Regimen Demonstrates Statistically Significant Relative Risk Reduction of Death or Graft Loss over Cyclosporine Regimen in Kidney Transplant at noodls
10:00AM  Long-Term, 7-Year Study of Nulojix® (belatacept) Regimen Demonstrates Statistically Significant Relative Risk Reduction of Death or Graft Loss over Cyclosporine Regimen in Kidney Transplant Business Wire
May-05-15 10:06PM  Is Novartis an Up-and-Coming Oncology Powerhouse?
03:25PM  New CEO takes over evolving drugmaker Bristol-Myers Squibb
10:50AM  Top Credit Suisse Major Pharma Stock Picks to Buy at 24/7 Wall St.
09:34AM  BRISTOL MYERS SQUIBB CO Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:51AM  Credit Suisse: We Prefer Pfizer, Bristol Over Pharma Peers
May-04-15 03:54PM  Bristol-Myers Squibb to Present at Bank of America Merrill Lynch 2015 Health Care Conference at noodls
03:38PM  Bristol-Myers Squibb to Present at Bank of America Merrill Lynch 2015 Health Care Conference Business Wire
09:40AM  U.S. top court rejects hepatitis B drug patent case Reuters
09:30AM  The Zacks Analyst Blog Highlights: Bristol-Myers Squibb, Biogen, Actelion and Horizon Pharma - Press Releases
May-01-15 02:50PM  Bristol-Myers' Supplemental BLA for Opdivo Accepted by FDA - Analyst Blog
01:04PM  BRISTOL MYERS SQUIBB CO Financials
Apr-30-15 08:13PM  10-Q for Bristol-Myers Squibb Co. at Company Spotlight
Apr-29-15 10:57PM  Bristol-Myers Squibb Company announced about Opdivo (nivolumab).(172KB) at noodls
06:37PM  Bristol-Myers Squibb Prices 1.15 Billion of Senior Notes at noodls
06:30PM  Bristol-Myers Squibb Prices 1.15 Billion of Senior Notes Business Wire
06:15PM  Final Glance: Pharmaceuticals companies
05:37PM  U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Patients with Previously Untreated Advanced Melanoma at noodls
05:00PM  U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Patients with Previously Untreated Advanced Melanoma Business Wire
04:15PM  Merck & Co. (MRK) Earnings Analysis: By the Numbers
03:44PM  Pfizer (PFE) Earnings Analysis: By the Numbers
03:23PM  Bristol-Myers Squibb (BMY) Earnings Analysis: By the Numbers
02:53PM  Midday Glance: Pharmaceuticals companies
10:45AM  Early Glance: Pharmaceuticals companies
10:41AM  Bristol-Myers Squibb to Take Part in Deutsche Bank Global Health Care Conference at noodls
10:00AM  Bristol-Myers Squibb to Take Part in Deutsche Bank Global Health Care Conference Business Wire
08:23AM  Bristol-Myers Squibb's Next 8 Months: What To Expect
05:59AM  Hepatitis C cure rate of 94% achieved in patients post-liver transplant and up to 94% in those with advanced cirrhosis (Child-Pugh Class A and B) following 12-week, oral treatment with combination daclatasvir and sofosbuvir once daily, plus CNW Group
12:21AM  Pfizer, Merck and Bristol-Myers Squibb Report Solid Results at The Wall Street Journal
Apr-28-15 07:00PM  New meds help drugmakers AAP
06:49PM  Strong Merck cancer drug sales upstage rival Bristol-Myers
04:47PM  New meds help drugmakers weather strong dollar, other issues
04:44PM  Major Drug Companies Report Solid Results at The Wall Street Journal
04:36PM  Will Schizophrenia and Bipolar Patients Trust Generic Abilify? at 24/7 Wall St.
04:00PM  FDA approves generic versions of antipsychotic drug Abilify Reuters
02:51PM  FDA approves first generic for blockbuster antipsychotic Abilify Reuters
01:43PM  Pfizer, despite dollar and generics fight, still impresses
12:27PM  Merck hurdles Wall Street forecasts
11:02AM  High-profile Bristol cancer drug disappoints, shares off
10:43AM  Bristol-Myers Q1 Earnings Beat Driven by Strong Sales - Analyst Blog
10:10AM  Bristol-Myers Squibb (BMY) Stock Declines Despite Strong Financial Quarter at TheStreet
09:02AM  Cancers Six-Figure Potential Blockbusters Lift Drugmaker Sales at Bloomberg
08:42AM  Bristol-Myers (BMY) Beats on Q1 Earnings, Share Up - Tale of the Tape
08:09AM  Innovation driving big pharma: Pro
08:06AM  Bristol-Myers post EPS, revenue beat
08:05AM  Polcari: Quiet, Churning, Apple Watching, Awaiting The Fed at Investor's Business Daily
08:01AM  Early movers: BP, F, AAPL, BMY, COH, PFE & more at CNBC
07:48AM  Bristol-Myers Squibb Announces Cash Tender Offer For Up to $400 Million Aggregate Principal Amount of its Outstanding Debt Securities Business Wire
07:39AM  Bristol-Myers beats Street 1Q forecasts
07:39AM  Bristol-Myers tops forecasts, helped by Abilify royalty adjustment
07:31AM  BRISTOL MYERS SQUIBB CO Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E
07:31AM  Bristol-Myers Reports Higher Sales, Earnings at The Wall Street Journal
07:30AM  Bristol-Myers Squibb Reports First Quarter Financial Results Business Wire
07:30AM  Bristol-Myers First-Quarter Sales Grow as Abilify Tops Estimates at Bloomberg
07:07AM  Q1 2015 Bristol-Myers Squibb Co Earnings Release - Before Market Open
Apr-27-15 09:33PM  Can big pharma's earnings today keep market bulls engaged?
05:30PM  Big pharma, big earnings?
04:39PM  Markets end lower...
04:27PM  Bristol-Myers Squibb Earnings: Experts & Crowd Expect 10% EPS Growth
03:44PM  Gilead and Bristol-Myers Reveal Positive Data on HCV Drugs - Analyst Blog
03:04PM  Will Bristol-Myers (BMY) Earnings Streak Continue in Q1? - Analyst Blog
01:42PM  Will Merck's (MRK) Q1 Earnings be Hit by Generics & Currency? - Analyst Blog
01:33PM  4 Drug Giants Reporting Earnings This Week at Investor's Business Daily
10:38AM  Moody's: Outlook stable for pharmaceuticals; M&A activity to remain strong at Moody's
10:18AM  The market in a minute: 500 earnings reports ahead at MarketWatch
10:04AM  GSK readies "bubble boy" drug as big pharma bets on gene therapy Reuters
09:39AM  Bristol-Myers hepatatis C therapy with Sovaldi meets study goals at MarketWatch
08:14AM  ALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class A or B) Business Wire
12:01AM  Bristol-Myers Squibb Receives Positive CHMP Opinion in the European Union for Opdivo (nivolumab) for the Treatment of Advanced Melanoma in Both First-Line and Previously Treated Patients(246KB) at noodls
Apr-25-15 05:00PM  Bristol-Myers says hepatitis C drug combination succeeds in study Reuters
10:08AM  ALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class A or B) at noodls
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecules, and biologics in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; immunoscience; and cardiovascular. The company's products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Erbitux, an IgG1 monoclonal antibody that targets and blocks the epidermal growth factor receptor; and Sprycel, a multi-targeted tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia. Its products also comprise Yervoy, a monoclonal antibody for the treatment of patients with metastatic melanoma; Abilify, an antipsychotic agent for adult patients with schizophrenia, bipolar mania disorder, and major depressive disorder; Orencia for use in treating patients with moderately to severely active rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders. In addition, it is developing Opdivo, a human monoclonal antibody, which is in Phase III trials for non-small cell lung cancer, renal cell cancer, and melanoma; Beclabuvir, a non-nucleoside NS5B inhibitor that is in Phase III development for the treatment of HCV; Elotuzumab, a humanized monoclonal antibody, which is in Phase III trials for the treatment of multiple myeloma; and BMS-663068, an investigational compound that is being studied in HIV-1. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
JUDGE ANN POWELLSVP, Global Human ResourcesApr 01Option Exercise0.001,55409,047Apr 03 03:39 PM
Cuss Francis MEVP & CSOMar 16Option Exercise25.52114,0102,909,160380,699Mar 17 05:54 PM
Cuss Francis MEVP & CSOMar 16Sale67.81114,6667,775,501266,033Mar 17 05:54 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 16Sale67.087,000469,56022,218Mar 16 07:02 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 13Sale66.6759139,40231,015Mar 16 07:01 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 13Sale66.795,000333,97229,218Mar 16 07:02 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 10Option Exercise0.002,068042,368Mar 12 06:53 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Option Exercise0.005,287035,218Mar 12 06:54 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 10Option Exercise0.003,271052,348Mar 12 06:54 PM
Cuss Francis MEVP & CSOMar 10Option Exercise0.008,0190269,160Mar 12 06:54 PM
Caforio GiovanniChief Operating OfficerMar 10Option Exercise0.0010,579071,322Mar 12 06:54 PM
Nielsen AnneChief Compliance & Ethics OffMar 10Option Exercise0.001,788050,485Mar 12 06:55 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 10Option Exercise0.005,212058,799Mar 12 06:55 PM
Caldarella Joseph CSVP & ControllerMar 10Option Exercise0.002,977076,835Mar 12 06:55 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 10Option Exercise0.0013,2390184,290Mar 12 06:55 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 10Option Exercise0.0048,8500411,731Mar 12 06:56 PM
LEUNG SANDRAGeneral Counsel & SecretaryMar 10Option Exercise0.009,9970307,535Mar 12 06:53 PM
JUDGE ANN POWELLSVP, Human ResourcesMar 10Option Exercise0.004,54608,057Mar 12 06:53 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 10Sale65.8410,343680,94231,606Mar 12 06:53 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 06Option Exercise0.001,043059,141Mar 10 04:53 PM
Caldarella Joseph CSVP & ControllerMar 06Option Exercise0.001,931074,668Mar 10 04:53 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 06Option Exercise0.001,043040,624Mar 10 04:51 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 06Option Exercise0.0029,2400374,863Mar 10 04:51 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 06Option Exercise0.002,528030,053Mar 10 04:52 PM
Nielsen AnneChief Compliance & Ethics OffMar 06Option Exercise0.00724048,631Mar 10 04:53 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 06Option Exercise0.002,390054,339Mar 10 04:53 PM
Cuss Francis MEVP & CSOMar 06Option Exercise0.003,0090261,937Mar 10 04:54 PM
Caforio GiovanniChief Operating OfficerMar 06Option Exercise0.002,889061,986Mar 10 04:52 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 06Option Exercise0.007,3230171,251Mar 10 04:52 PM
LEUNG SANDRAGeneral Counsel & SecretaryMar 06Option Exercise0.005,5730298,970Mar 10 04:52 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 06Sale66.2410,468693,45249,031Mar 10 04:53 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 02Option Exercise0.008,250060,609Mar 04 09:38 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 02Option Exercise0.008,249043,860Mar 04 09:38 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 02Option Exercise0.0019,995034,176Mar 04 09:38 PM
LEUNG SANDRAGeneral Counsel & SecretaryMar 02Option Exercise0.0044,0840316,255Mar 04 09:39 PM
Caforio GiovanniChief Operating OfficerMar 02Option Exercise0.0022,851070,125Mar 04 09:37 PM
Cuss Francis MEVP & CSOMar 02Option Exercise0.0023,8030270,105Mar 04 09:37 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 02Option Exercise0.0018,907060,423Mar 04 09:37 PM
Nielsen AnneChief Compliance & Ethics OffMar 02Option Exercise0.005,725050,278Mar 04 09:37 PM
Caldarella Joseph CSVP & ControllerMar 02Option Exercise0.0015,271079,730Mar 04 09:36 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 02Option Exercise0.00231,2800643,964Mar 04 09:36 PM
Nielsen AnneChief Compliance & Ethics OffMar 02Option Exercise0.001,033044,363Mar 04 05:14 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 02Option Exercise0.009,7470108,016Mar 04 05:14 PM
Cuss Francis MEVP & CSOMar 02Option Exercise0.003,7030245,358Mar 04 05:14 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 02Option Exercise0.003,182040,705Mar 04 05:14 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 02Option Exercise0.001,360051,827Mar 04 05:12 PM
Caldarella Joseph CSVP & ControllerMar 02Option Exercise0.002,475064,025Mar 04 05:13 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 02Option Exercise0.001,174035,654Mar 04 05:13 PM
Caforio GiovanniChief Operating OfficerMar 02Option Exercise0.001,494046,893Mar 04 05:13 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 02Option Exercise0.0033,5310416,594Mar 04 05:13 PM
LEUNG SANDRAGeneral Counsel & SecretaryFeb 17Option Exercise25.4515,000381,750275,656Feb 18 05:32 PM
LEUNG SANDRAGeneral Counsel & SecretaryFeb 17Sale60.3911,746709,282263,910Feb 18 05:32 PM
Moed Samuel JSVP, Strat Plan & AnalysisFeb 12Sale59.263,880229,93334,480Feb 13 04:38 PM
Moed Samuel JSVP, Strat Plan & AnalysisFeb 06Option Exercise22.1427,938618,54759,838Feb 10 06:11 PM
Moed Samuel JSVP, Strat Plan & AnalysisFeb 06Sale60.1521,4781,291,98838,360Feb 10 06:11 PM
CORNELIUS JAMES MDirectorJan 30Sale60.6050,0003,029,975119,464Feb 03 06:18 PM
ANDREOTTI LAMBERTOChief Executive OfficerJan 29Option Exercise25.45112,5002,863,125473,309Feb 02 07:05 PM
CAMPBELL LEWIS BDirectorJan 29Option Exercise26.252,50065,6252,500Feb 02 07:05 PM
Schmukler Louis SPres., Global Mfg. & SupplyJan 29Sale60.735,250318,85014,182Feb 02 07:05 PM
ANDREOTTI LAMBERTOChief Executive OfficerJan 29Sale61.1490,2465,518,001383,063Feb 02 07:05 PM
CAMPBELL LEWIS BDirectorJan 29Sale60.892,500152,2270Feb 02 07:05 PM
Elicker John ESVP Pub Affairs & Inv RelationJan 03Option Exercise0.00952050,808Jan 06 06:56 PM
ANDREOTTI LAMBERTOChief Executive OfficerDec 05Sale60.3175,0004,522,944360,809Dec 05 05:39 PM
ANDREOTTI LAMBERTOChief Executive OfficerNov 05Sale57.7975,0004,334,153435,809Nov 07 05:13 PM
Cuss Francis MEVP & CSONov 02Option Exercise0.006,6660245,112Nov 04 05:42 PM
Bancroft Charles AEVP & Chief Financial OfficerNov 01Option Exercise0.003,102099,666Nov 04 05:43 PM
ANDREOTTI LAMBERTOChief Executive OfficerOct 24Sale53.0050,0002,650,000510,809Oct 28 04:23 PM
CORNELIUS JAMES MDirectorOct 15Sale48.92100,0004,892,000169,041Oct 17 05:16 PM
ANDREOTTI LAMBERTOChief Executive OfficerOct 06Sale50.9950,0002,549,485560,809Oct 08 06:02 PM
Schmukler Louis SPres., Global Mfg. & SupplyOct 03Option Exercise0.0013,934025,565Oct 06 05:52 PM
Cuss Francis MEVP & CSOSep 16Option Exercise25.1763,6671,602,575302,113Sep 16 05:18 PM
Cuss Francis MEVP & CSOSep 16Sale50.7763,6673,232,074238,446Sep 16 05:18 PM
Caforio GiovanniChief Operating OfficerSep 15Sale49.8726,6911,331,15540,755Sep 16 05:18 PM
Caldarella Joseph CSVP & ControllerSep 10Sale51.037,415378,37761,550Sep 10 04:30 PM
ANDREOTTI LAMBERTOChief Executive OfficerSep 08Sale51.0550,0002,552,430610,809Sep 10 04:30 PM
von Autenried PaulSVP, Enterp. Services & CIOAug 19Sale49.8920,000997,85137,523Aug 19 05:08 PM
Moed Samuel JSVP, Strat Plan & AnalysisJul 28Option Exercise27.0119,650530,74759,652Jul 30 04:40 PM
Moed Samuel JSVP, Strat Plan & AnalysisJul 28Sale49.3225,7521,270,03733,900Jul 30 04:40 PM
DANIELS BRIANSVP Global Dev & Med AffairsJul 01Option Exercise0.004,671096,477Jul 02 06:35 PM